NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00546000,Cutivate Lotion HPA Axis Pediatric Study,https://clinicaltrials.gov/study/NCT00546000,,COMPLETED,"A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.",YES,Atopic Dermatitis,DRUG: Fluticasone propionate 0.05% lotion,"Post Treatment Serum Cortisol Values Will be Compared., The primary safety parameter was the response to the CST at the end of treatment/final visit. Blood samples were collected prior to injection of cosyntropin and post-injection. Post-CST stimulation cortisol level â‰¤ 18micrograms/dL was considered as evidence of adrenal suppression., Up to 29 days of treatment","Record Skin Atrophy, Pigmentation Change, Hematological and Chemistry Assessments, and Changes in Atopic Dermatitis Severity, The frequency distributions of the presence/absence of adverse events associated with signs of atrophy and pigmentation changes were summarized with frequency counts. Hematology and Chemistry Assessments were summarized in shift tables. Signs and symptoms of AD were summarized at each visit., Over 5-6 visits following the baseline visit through the end of treatment between Day 22-29",,Fougera Pharmaceuticals Inc.,,ALL,CHILD,PHASE4,56,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,ALT 0434-01-01,2007-07,2008-12,2008-12,2007-10-18,2014-06-25,2014-07-24,"Centre for Health Care Medical Associates, Poway, California, 92064, United States|Rady Children's Hospital, San Diego, San Diego, California, 92123, United States|University of Miami, Dept. of Dermatology, Miami, Florida, 33125, United States|Adult & Pediatric Dermatology, Overland Park, Kansas, 66211, United States|Dermatology Center for Children and Young Adults, Eagan, Minnesota, 55121-1176, United States|Central Dermatology, Saint Louis, Missouri, 63117, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States|Paddington Testing Company, Inc, Philadelphia, Pennsylvania, 19103, United States|University of Texas Medical Branch, Galveston, Texas, 77555-0783, United States|University of Texas Health Science Center, Houston, Texas, 77030, United States",
